GC
SNDX icon

Guggenheim Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Guggenheim Capital’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$375K Buy
16,056
+1,518
+10% +$33K ﹤0.01% 1304
2025
Q4 		$305K Buy
14,538
+2,395
+20% +$41.8K ﹤0.01% 1521
2025
Q3 		$187K Sell
12,143
-605
-5% -$7.92K ﹤0.01% 1525
2025
Q2 		$119K Buy
12,748
+258
+2% +$2.84K ﹤0.01% 1553
2025
Q1 		$153K Buy
12,490
+609
+5% +$8.59K ﹤0.01% 1569
2024
Q4 		$157K Buy
+11,881
New +$203K ﹤0.01% 1623

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Guggenheim Capital's SNDX Position: Q1 2026 in Review

Guggenheim Capital increased its Syndax Pharmaceuticals (SNDX) stake by 10% in Q1 2026, buying an estimated $33K and bringing the position to 16,056 shares worth $375K. The position accounts for ﹤0.01% of the portfolio, ranked #1304.

Guggenheim Capital first reported a position in SNDX in Q4 2024 and has held it in 6 quarters since. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Guggenheim Capital held 16,056 shares of Syndax Pharmaceuticals worth $375K as of Q1 2026.
  • Guggenheim Capital bought 1,518 Syndax Pharmaceuticals shares in Q1 2026, an estimated $33K.
  • Syndax Pharmaceuticals made up ﹤0.01% of Guggenheim Capital's portfolio in Q1 2026, its #1304 holding.
  • Guggenheim Capital first reported a position in Syndax Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.